Dengue virus is a major mosquito-borne pathogen that causes clinical manifestations ranging from asymptomatic infection to severe dengue, including dengue hemorrhagic fever and dengue shock syndrome. Disease severity is strongly associated with antibody-dependent enhancement (ADE), in which pre-existing non-neutralizing antibodies promote Fcγ receptor-mediated viral entry into immune cells, resulting in enhanced viral replication, immune dysregulation, endothelial dysfunction, and vascular leakage. Emerging evidence indicates that microRNAs (miRNAs) are key post-transcriptional regulators of host immune responses, inflammatory signaling, and vascular integrity during dengue virus infection. This review summarizes current evidence on the interplay between ADE and miRNA-mediated regulation of dengue pathogenesis, with emphasis on innate and adaptive immunity, Fcγ receptor signaling, cytokine responses, and endothelial barrier dysfunction. We also highlight circulating and tissue-specific miRNAs with potential value as biomarkers for disease severity and prognosis, and discuss emerging miRNA-based therapeutic strategies, including miRNA mimics and inhibitors, as host-directed approaches to modulate ADE-associated pathways. Improved understanding of miRNA regulatory networks may facilitate the development of novel biomarkers and targeted therapeutic strategies for severe dengue.
No takes yet. Share an insight, caveat, or question.
Babai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: